FMP
NASDAQ
1.74 USD
0.13 (7.47%)
Dr. Zheng Wei Ph.D.
Healthcare
Biotechnology
https://www.connectbiopharm.com
NASDAQ
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmu...
0001835268
US2075231017
207523101
East R&D Building
86 512 5357 7866
CN
100
Mar 19, 2021
0001835268
NASDAQ
Biotechnology
Healthcare
207523101
US2075231017
CN
1.74
-0.73
131.8k
95.82M
-
0.535-2.84
1.38
-
-
-
-
-1.13
-
https://www.connectbiopharm.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.